摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3-甲氧基-2-噻吩基)甲胺 | 946409-37-6

中文名称
1-(3-甲氧基-2-噻吩基)甲胺
中文别名
2-(叔-丁氧基羰基-甲基-氨基)-5-甲基-苯甲酸
英文名称
(3-methoxythiophen-2-yl)methylamine
英文别名
(3-Methoxythien-2-yl)methylamine;(3-methoxythiophen-2-yl)methanamine
1-(3-甲氧基-2-噻吩基)甲胺化学式
CAS
946409-37-6
化学式
C6H9NOS
mdl
——
分子量
143.21
InChiKey
GDDVAKBOBBYCLK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    220.7±25.0 °C(Predicted)
  • 密度:
    1.165±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    63.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090

SDS

SDS:7c81b96aad28f1f1aca3b9422009fdff
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Pyrazole compounds and their use as antidiabetes agents
    申请人:Takagi Masaki
    公开号:US20070032529A1
    公开(公告)日:2007-02-08
    The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.
    本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物,用作糖尿病的治疗或预防剂,所述吡唑化合物由以下通用式(I)表示:其中环Q代表芳基或杂芳基,R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基,R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基,R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、氨基、酰胺基或C1-6烷基磺酰胺基,R4和R5彼此相同或不同,代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等,或其药理学上可接受的盐。
  • 阿片受体激动剂及其应用
    申请人:四川海思科制药有限公司
    公开号:CN109206417B
    公开(公告)日:2023-01-03
    本申请描述了可以用作阿片受体配体的化合物及其盐,及制备方法和含有该化合物的组合物,及其可以作为μ阿片受体激动剂的用途,用于治疗μ阿片受体介导的相关疾病,如疼痛和疼痛相关的紊乱。
  • METHOD FOR PREPARING OXASPIROCYCLE DERIVATIVE, AND INTERMEDIATE THEREOF
    申请人:JIANGSU HENGRUI MEDICINE CO., LTD.
    公开号:US20200308151A1
    公开(公告)日:2020-10-01
    A method for preparing an oxaspirocycle derivative and an intermediate thereof are described. The method reduces reaction steps, improves reaction yield, is simple and easy to operate, and is favorable for industrial large-scale production.
    本文描述了一种制备氧杂螺环衍生物及其中间体的方法。该方法减少了反应步骤,提高了反应产率,操作简单易行,非常适合工业大规模生产。
  • PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
    申请人:Japan Tobacco, Inc.
    公开号:EP1884513A1
    公开(公告)日:2008-02-06
    The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R1 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, R2 represents a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or an azido group, R3 represents a halogen atom, a hydroxyl group, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C1-6 alkylsulfonylamino group, R4 and R5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group, a C3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.
    本发明提供了一种具有肝糖原磷酸化酶抑制活性并可用作糖尿病治疗或预防剂的吡唑化合物,该吡唑化合物由以下通式(I)表示: 其中环 Q 代表芳基或杂芳基,R1 代表氢原子、卤素原子、C1-6 烷基或 C1-6 烷氧基,R2 代表卤素原子、C1-6 烷基、C1-6 烷氧基或叠氮基,R3 代表卤素原子、羟基、C1-6 烷基、卤代 C1-6 烷基、C1-6 烷氧基、叠氮基、氨基、酰氨基或酰胺基、R4 和 R5 彼此相同或不同,代表氢原子、取代或未取代的 C1-6 烷基、C3-8 环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14 芳基、杂芳基或类似基团,或其药理学上可接受的盐。
  • Method for preparing oxaspirocycle derivative, and intermediate thereof
    申请人:JIANGSU HENGRUI MEDICINE CO., LTD.
    公开号:US11111236B2
    公开(公告)日:2021-09-07
    A method for preparing an oxaspirocycle derivative and an intermediate thereof are described. The method reduces reaction steps, improves reaction yield, is simple and easy to operate, and is favorable for industrial large-scale production.
    本文介绍了一种制备氧杂螺环衍生物及其中间体的方法。该方法减少了反应步骤,提高了反应产率,操作简单方便,有利于工业化大规模生产。
查看更多